Bempedoic Acid and Cardiovascular Health
Insights from the CLEAR Trials and Beyond
Publication
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388:1353-1364.
Publication
Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA,. 2023 Jul 11;330(2):131-140.
Publication
Nicholls SJ, Nelson AJ, Lincoff AM, et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024 Mar 1;9(3):245-253.
Publication
Bays H, Bloedon LT, Lin G., et al. Safety of Bempedoic Acid in Patients at High Cardiovascular Risk and with Statin Intolerance. J Clin Lipidol. 2023;S1933-2874(23)00313-6.
Publication
Ray KK, Nicholls SJ, Li N, et al. Efficacy and Safety of Bempedoic Acid Among Patients With and Without Diabetes: Prespecified Analysis of the CLEAR Outcomes Randomised Trial. Lancet Diabetes Endocrinol. 2024 Jan;12(1):19-28.
Publication
Lincoff AM, Kausik AR, Sasiela WJ, et al. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. J Am Coll Cardiol. 2024; 84(2): 152-162.
Publication
Cho L, Plutzky J, Brennan D, et al. Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex. Circulation. 2024 May 28;149(22):1775-1777.
Publication
Ridker, PM, Lei L, Louie MJ, et al. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients with Stain Intolerance. Circulation. 2024 Jan 2;149(1):28-35.
Publication
Singh A, Laffin LJ, Sarraju AA, et al. Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial. Clinical Cardiology. 2024 Aug;47(8):e24328.
Publication
Rodriguez F, Cho L, Foody J, et al. Characteristics and Outcomes for Hispanic/Latinx Participants with Statin Intolerance Receiving Bempedoic Acid. JACC. 2024 May, 83 (21) 2130–2132.
Publication
Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021 May;235:104-112. Epub 2020 Oct 24.
Publication
Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780–1788.
Publication
Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-32.
Publication
Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195-203.
Publication
Laufs U, Banach M, Mancini J, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. JAMA. 2019;8:e011662.
Publication
Ballantyne CM, Banach M, Bays HE, et al. Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol 2022;174:1−11.
Publication
Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. E Pub; July 29, 2019.
Publication
Bays HE, Banach M, Catapano AL, et al. Bempedoic Acid Safety Analysis: Pooled Data from Four Phase 3 Clinical Trials. J Clin Lipidol. 2020;14(5):649-659.e6.
Publication
Duell PB, Banach M, Catapano AL, et al. Efficacy And Safety of Bempedoic Acid In Patients With Heterozygous Familial Hypercholesterolemia: Analysis of Pooled Patient-Level Data From Phase 3 Clinical Trials. J Clin Lipidol. 2024; epub ahead of print. Feb 29, 2024.
Publication
Gunn LH, McKay AJ, Feng A, et al. Estimated Cardiovascular Benefits of Bempedoic Acid in Patients with Established Cardiovascular Disease. Atherosclerosis Plus. 2022;49:20-27.
Publication
Shapiro MD, Taub PR, Louie MJ, et al. Efficacy and Safety of Bempedoic Acid in Patients With and Without Metabolic Syndrome: Pooled Analysis of Data From Four Phase 3 Clinical Trials. Atherosclerosis. 2023 Aug:378:117182.
Publication
Anne C. Goldberg, Maciej Banach, Alberico L. Catapano, et al. Evaluation of the Efficacy and Safety of Bempedoic Acid in Women and Men: Pooled Analyses from Phase 3 Trials. Atherosclerosis. 2023 Jul:384:117192.
Publication
Stroes E, Bays H, Banach M, Catapano A, Duell PB, et al. Bempedoic Acid Lowers High-Sensitivity C-Reactive Protein and Low-Density Lipoprotein Cholesterol: Analysis of Pooled Data from Four Phase 3 Clinical Trials. Atherosclerosis. 2023 Apr 3;373:1-9.
Publication
Duell PB, Banach M, Catapano AL, et al. Efficacy and Safety of Bempedoic Acid in Patients with Heterozygous Familial Hypercholesterolemia: Analysis of Pooled Patient-Level Data from Phase 3 Clinical Trials. Clin Lipidology 2024 Jan 1-13.
© 2025 Wolters Kluwer. All right reserved.